SG10201912408WA - Chimeric polypeptides and methods of altering their localisation in the cell membrane - Google Patents

Chimeric polypeptides and methods of altering their localisation in the cell membrane

Info

Publication number
SG10201912408WA
SG10201912408WA SG10201912408WA SG10201912408WA SG10201912408WA SG 10201912408W A SG10201912408W A SG 10201912408WA SG 10201912408W A SG10201912408W A SG 10201912408WA SG 10201912408W A SG10201912408W A SG 10201912408WA SG 10201912408W A SG10201912408W A SG 10201912408WA
Authority
SG
Singapore
Prior art keywords
localisation
altering
methods
cell membrane
chimeric polypeptides
Prior art date
Application number
SG10201912408WA
Other languages
English (en)
Inventor
Stephen Santoro
Scott Coyle
Levi Rupp
Peter Emtage
Original Assignee
Cell Design Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Design Labs Inc filed Critical Cell Design Labs Inc
Publication of SG10201912408WA publication Critical patent/SG10201912408WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A61K39/001112—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7153—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for colony-stimulating factors [CSF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Developmental Biology & Embryology (AREA)
SG10201912408WA 2017-03-28 2018-03-28 Chimeric polypeptides and methods of altering their localisation in the cell membrane SG10201912408WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762477733P 2017-03-28 2017-03-28
US201762587262P 2017-11-16 2017-11-16

Publications (1)

Publication Number Publication Date
SG10201912408WA true SG10201912408WA (en) 2020-02-27

Family

ID=62090037

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201912408WA SG10201912408WA (en) 2017-03-28 2018-03-28 Chimeric polypeptides and methods of altering their localisation in the cell membrane
SG11201908618S SG11201908618SA (en) 2017-03-28 2018-03-28 Chimeric polypeptides and methods of altering their localisation in the cell membrane

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201908618S SG11201908618SA (en) 2017-03-28 2018-03-28 Chimeric polypeptides and methods of altering their localisation in the cell membrane

Country Status (14)

Country Link
US (1) US11111310B2 (ar)
EP (1) EP3601330A1 (ar)
JP (3) JP2020512009A (ar)
KR (4) KR102475696B1 (ar)
CN (1) CN110678480A (ar)
AU (3) AU2018244592C1 (ar)
BR (1) BR102018006205A2 (ar)
CA (1) CA3058262A1 (ar)
IL (1) IL269433A (ar)
JO (1) JOP20180027A1 (ar)
SG (2) SG10201912408WA (ar)
TW (1) TWI811212B (ar)
UY (1) UY37644A (ar)
WO (1) WO2018183551A1 (ar)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA49355A (fr) * 2017-03-27 2020-02-05 Hoffmann La Roche Formats de récepteurs de liaison d'antigène améliorés
US11485789B2 (en) * 2017-11-12 2022-11-01 Jay H. Choi Modular, controlled single chain variable fragment antibody switch
US20240122980A1 (en) * 2019-10-18 2024-04-18 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Use of tim-3 cytoplasmic tail in chimeric antigen receptors
CN111995689B (zh) * 2020-08-27 2023-05-05 深圳市体内生物医药科技有限公司 一种基因修饰的免疫细胞及其制备方法和应用
CN114149510B (zh) * 2021-10-29 2024-01-30 上海鑫湾生物科技有限公司 一种条件控制的可剪接嵌合抗原受体分子及其应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
JP3700791B2 (ja) * 1994-05-26 2005-09-28 小野薬品工業株式会社 Ｆａｓ抗原融合蛋白、その蛋白をコードするＤＮＡ、そのＤＮＡを含むベクター、そのベクターで形質転換された宿主細胞、そのベクターを有効成分とする治療剤、およびその宿主細胞を用いるスクリーニング方法
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
EP0910648A1 (en) * 1996-04-15 1999-04-28 The Board Of Trustees Of The Leland Stanford Junior University Soluble 7-transmembrane domain g-protein-coupled receptor compositions and methods
JP2002153287A (ja) * 2000-11-24 2002-05-28 Daicel Chem Ind Ltd 内分泌撹乱物質結合領域を細胞の表層に有する微生物およびその応用方法
WO2002095405A1 (en) 2001-05-21 2002-11-28 The Regents Of The University Of California Membrane-resident steroid receptors and methods of use thereof
EP1912069A3 (en) * 2002-06-05 2008-07-09 Sopherion Therapeutics, Inc. Method to screen ligands using eukaryotic cell display
WO2006012414A2 (en) 2004-07-20 2006-02-02 Critical Therapeutics, Inc. Novel polyadenylation signal for use in expression vectors
EP1885858A2 (en) * 2005-05-19 2008-02-13 Bayer Schering Pharma Aktiengesellschaft Treatment of disease using an improved regulated expression system
WO2006127972A2 (en) * 2005-05-26 2006-11-30 Dana-Farber Cancer Institute, Inc. Modulation of muc1-dependent anti-estrogen resistance
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
JP5674654B2 (ja) 2008-07-08 2015-02-25 アッヴィ・インコーポレイテッド プロスタグランジンｅ２二重可変ドメイン免疫グロブリンおよびその使用
EP2473524A4 (en) 2009-09-01 2013-05-22 Abbott Lab IMMUNOGLOBULINE WITH DOUBLE VARIABLE DOMAIN AND ITS USE
KR20140015139A (ko) 2009-10-15 2014-02-06 애브비 인코포레이티드 이원 가변 도메인 면역글로불린 및 이의 용도
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
CN103298834A (zh) 2010-08-03 2013-09-11 Abbvie公司 双重可变结构域免疫球蛋白及其用途
PT3300745T (pt) 2013-02-15 2019-11-27 Univ California Recetor de antigénio quimérico e métodos de utilização do mesmo
AU2014236726A1 (en) * 2013-03-14 2015-09-17 Bellicum Pharmaceuticals, Inc. Methods for controlling T cell proliferation
EP3027204B1 (en) * 2013-07-29 2022-01-05 2seventy bio, Inc. Multipartite signaling proteins and uses thereof
CA2937750A1 (en) * 2014-02-14 2015-08-20 Bellicum Pharmaceuticals, Inc. Methods for activating t cells using an inducible chimeric polypeptide
US20170081411A1 (en) 2014-03-15 2017-03-23 Novartis Ag Regulatable chimeric antigen receptor
GB201405845D0 (en) * 2014-04-01 2014-05-14 Ucl Business Plc Signalling system
US11041021B2 (en) * 2014-05-23 2021-06-22 University Of Florida Research Foundation, Incorporated Car based immunotherapy
US10538568B2 (en) * 2014-11-04 2020-01-21 The Trustees Of The University Of Pennsylvania Methods and compositions of a follicle stimulating hormone receptor immunoreceptor
MX2017010721A (es) * 2015-02-24 2018-08-28 Univ California Interruptores transcripcionales activados mediante unión y métodos para su uso.
CA2979724A1 (en) * 2015-03-30 2016-10-06 Intrexon Corporation Ligand inducible polypeptide coupler system
BR112018002189A2 (pt) * 2015-08-24 2018-09-18 Cellectis receptores antigênicos quiméricos com funções controláveis integradas
EP3399991A4 (en) * 2016-01-08 2019-08-07 The Regents of The University of California REQUIRES ACTIVE HETERODIMER POLYPEPTIDES AND METHOD FOR USE THEREOF

Also Published As

Publication number Publication date
BR102018006205A2 (pt) 2021-03-23
AU2018244592B2 (en) 2021-03-11
TW201840590A (zh) 2018-11-16
US11111310B2 (en) 2021-09-07
JP2022058725A (ja) 2022-04-12
CN110678480A (zh) 2020-01-10
JP7433348B2 (ja) 2024-02-19
KR20190133734A (ko) 2019-12-03
UY37644A (es) 2018-10-31
US20210395386A1 (en) 2021-12-23
IL269433A (en) 2019-11-28
KR20230004870A (ko) 2023-01-06
AU2023200894A1 (en) 2023-03-23
AU2018244592A1 (en) 2019-10-03
AU2021203626B2 (en) 2023-03-09
JP2020512009A (ja) 2020-04-23
JP2024054208A (ja) 2024-04-16
TWI811212B (zh) 2023-08-11
EP3601330A1 (en) 2020-02-05
US20180319890A1 (en) 2018-11-08
WO2018183551A1 (en) 2018-10-04
JOP20180027A1 (ar) 2019-01-30
KR102659440B1 (ko) 2024-04-24
KR102475696B1 (ko) 2022-12-09
AU2021203626A1 (en) 2021-07-01
KR20220002751A (ko) 2022-01-06
CA3058262A1 (en) 2018-10-04
SG11201908618SA (en) 2019-10-30
AU2018244592C1 (en) 2021-07-08
KR20240019863A (ko) 2024-02-14

Similar Documents

Publication Publication Date Title
IL273327A (en) Chimeric polypeptides and their uses
ZA202006500B (en) Materials and methods for engineering cells and uses thereof in immuno-oncology
IL275307B (en) Syntac polypeptides and their uses
HK1250481A1 (zh) 經過修飾的t細胞及其製備和使用方法
HRP20190028T1 (hr) Interleukin-2 fuzijski proteini i njihove primjene
PL3414787T3 (pl) Wstępnie litowane materiały elektrod i ogniwa wykorzystujące te materiały
EP3472208C0 (en) T-LYMPHOCYTE RECEPTORS AND THEIR USES
SG10201912408WA (en) Chimeric polypeptides and methods of altering their localisation in the cell membrane
HK1244460A1 (zh) 絲氨酸融合多肽和其使用方法
IL249368B (en) map44 polypeptides and structures based on natural antibodies and their uses
EP3218477A4 (en) Compositions and methods for expressing polypeptides on the surface of cells
EP3092248A4 (en) Fusion polypeptides and methods of use
GB201410031D0 (en) Polypeptides and uses thereof
IL273247A (en) New cell row and its uses
IL267565A (en) Binding polypeptides and methods for their preparation
GB201620194D0 (en) Electrode and electrchemical cell comprising the same
GB201719590D0 (en) Cell penetrating peptides and uses thereof
GB201616232D0 (en) Novel cell line and uses thereof
GB201712268D0 (en) Polypeptides and uses thereof
GB201712266D0 (en) polypeptides and uses thereof
GB201613143D0 (en) Polypeptides and uses thereof
GB201613142D0 (en) Polypeptides and uses thereof
GB201506317D0 (en) Hepatocyte-like cells and related cell lines
GB201518637D0 (en) Cell co-cultures and methods of making the same